文献速递头颈神经MR

脂肪抑制与非脂肪抑制T2映射预测甲状腺相关眼病静脉糖皮质激素治疗反应

T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy.
PubMed 文献 · Korean J Radiol · 2022-04-26

回顾79例活动性中重度甲状腺相关眼病患者,比较脂肪抑制与非脂肪抑制T2映射直方图参数及基线临床特征对静脉糖皮质激素治疗反应的预测价值。结果显示,病程、FS-95th百分位数和FS-峰度是独立预测因子,联合模型AUC为0.797,敏感度88.4%,特异度62.5%,显著优于影像模型(p=0.013)。脂肪抑制T2映射预测效能优于常规T2映射。

要点

  • 联合病程、FS-95th百分位数和FS-峰度的模型预测治疗反应AUC为0.797,敏感度88.4%,特异度62.5%。
  • 脂肪抑制T2映射预测效能显著优于常规T2映射(联合模型与影像模型AUC比较p=0.013)。
  • 治疗有效组较无效组病程更短,FS-峰度更低,FS-标准差更低,FS-第75、90、95百分位数T2弛豫时间更大。

核心结论

  • 联合病程、FS-95th百分位数和FS-峰度是活动性中重度甲状腺相关眼病患者静脉糖皮质激素治疗反应的潜在预测因子。
  • 脂肪抑制T2映射在预测治疗反应方面优于常规T2映射。

研究设计与样本

  • 回顾性纳入79例临床诊断为活动性中重度甲状腺相关眼病的患者(女47例,男32例;平均年龄±标准差46.1±10岁)。
  • 治疗有效组43例共86个眼眶,无效组36例共72个眼眶。
  • 比较两组基线临床特征及眼外肌脂肪抑制T2映射(FS T2 mapping)或非脂肪抑制T2映射(常规T2 mapping)的直方图参数。
  • 采用多因素分析筛选静脉糖皮质激素治疗反应的独立预测因子,并用受试者工作特征(ROC)曲线分析评估预测模型效能,模型间差异采用DeLong检验。

关键影像表现/征象

  • 治疗有效组较无效组病程更短,FS-峰度更低,FS-标准差更低。
  • 治疗有效组较无效组FS T2映射的第75、90、95百分位数T2弛豫时间更大,常规T2映射峰度更低。

诊断标准与关键数值

  • 联合模型(整合所有独立预测因子)预测治疗反应的ROC曲线下面积优化值为0.797,敏感度88.4%,特异度62.5%。
  • 联合模型预测效能显著优于影像模型(p=0.013)。

临床应用与阅片要点

  • 基线脂肪抑制T2映射的直方图参数(FS-95th百分位数、FS-峰度)结合病程,可能有助于预测活动性中重度甲状腺相关眼病患者对静脉糖皮质激素治疗的反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance of baseline clinical characteristics and pretherapeutic histogram parameters derived from T2 mapping of the extraocular muscles (EOMs) in the prediction of treatment response to intravenous glucocorticoid (IVGC) therapy for active and moderate-to-severe thyroid-associated ophthalmopathy (TAO) and to investigate the effect of fat-suppression (FS) in T2 mapping in this prediction.

MATERIALS AND METHODS: A total of 79 patients clinically diagnosed with active, moderate-to-severe TAO (47 female, 32 male; mean age ± standard deviation, 46.1 ± 10 years), including 43 patients with a total of 86 orbits in the responsive group and 36 patients with a total of 72 orbits in the unresponsive group, were enrolled. Baseline clinical characteristics and pretherapeutic histogram parameters derived from T2 mapping with FS (i.e., FS T2 mapping) or without FS (i.e., conventional T2 mapping) of EOMs were compared between the two groups. Independent predictors of treatment response to IVGC were identified using multivariable analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of the prediction models. Differences between the models were examined using the DeLong test.

RESULTS: Compared to the unresponsive group, the responsive group had a shorter disease duration, lower kurtosis (FS-kurtosis), lower standard deviation, larger 75th, 90th, and 95th (FS-95th) T2 relaxation times in FS mapping and lower kurtosis in conventional T2 mapping. Multivariable analysis revealed that disease duration, FS-95th percentile, and FS-kurtosis were independent predictors of treatment response. The combined model, integrating all identified predictors, had an optimized area under the ROC curve of 0.797, 88.4% sensitivity, and 62.5% specificity, which were significantly superior to those of the imaging model (p = 0.013).

CONCLUSION: An integrated combination of disease duration, FS-95th percentile, and FS-kurtosis was a potential predictor of treatment response to IVGC in patients with active and moderate-to-severe TAO. FS T2 mapping was superior to conventional T2 mapping in terms of prediction.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhai, Wang, Liu, et al. T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy. Korean J Radiol. 2022. PMID: 35555881. doi:10.3348/kjr.2021.0627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。